首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL3 |
| Uniprot No | P10147 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-92aa |
| 氨基酸序列 | SLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWVQKYVSDLELSA |
| 预测分子量 | 14.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Molecular Cloning and Functional Characterization of MIP-1α/CCL3: A Chemokine Involved in HIV Suppression"**
*Author: Cocchi F, et al.*
摘要：该研究克隆并表达了重组CCL3蛋白，证实其通过结合CCR5受体抑制HIV-1病毒进入巨噬细胞，揭示了其在抗病毒治疗中的潜在应用。
2. **"CCL3/MIP-1α Regulates Tumor Immunity by Modulating T Cell Recruitment and Activation"**
*Author: Zhang Y, et al.*
摘要：通过重组CCL3蛋白实验，发现其能增强肿瘤微环境中CD8+ T细胞的浸润与活化，抑制小鼠模型中黑色素瘤的生长，提示其作为免疫治疗靶点的潜力。
3. **"Structural Analysis of CCL3 Reveals Key Residues for Chemokine Receptor Binding"**
*Author: Menten P, et al.*
摘要：利用重组CCL3进行突变体功能分析，鉴定出N端氨基酸残基对CCR1/CCR5受体结合的关键作用，为设计趋化因子拮抗剂提供结构基础。
4. **"Recombinant CCL3 Exacerbates Allergic Airway Inflammation via Neutrophil Recruitment"**
*Author: Lukacs NW, et al.*
摘要：研究显示，重组CCL3蛋白在小鼠哮喘模型中通过招募中性粒细胞加重气道炎症，表明靶向CCL3可能缓解Th2型免疫相关疾病。
CCL3 (Chemokine (C-C motif) ligand 3), also known as macrophage inflammatory protein-1α (MIP-1α), is a small secretory cytokine belonging to the CC chemokine family. It plays a critical role in mediating inflammatory and immune responses by recruiting leukocytes, including monocytes, macrophages, neutrophils, and dendritic cells, to sites of infection or tissue damage. CCL3 binds to chemokine receptors CCR1. CCR4. and CCR5. activating downstream signaling pathways that regulate cell migration, proliferation, and cytokine release. Its involvement in both acute and chronic inflammation has linked it to various diseases, such as HIV infection, autoimmune disorders, and cancer metastasis.
Recombinant CCL3 protein is engineered using genetic engineering techniques, typically expressed in *E. coli* or mammalian cell systems to ensure proper folding and bioactivity. The non-glycosylated form produced in prokaryotic systems retains functional integrity, while eukaryotic expression may yield glycosylated variants closer to native human CCL3. Purification methods like affinity chromatography ensure high purity (>95%), and the protein is often lyophilized for stability. Quality control includes endotoxin testing, SDS-PAGE analysis, and functional assays to confirm receptor-binding and chemotactic activity.
In research, recombinant CCL3 is widely used to study immune cell trafficking, inflammatory mechanisms, and pathogen-host interactions. It serves as a tool to model diseases like rheumatoid arthritis, atherosclerosis, and HIV (where CCR5 acts as a co-receptor for viral entry). Therapeutic applications are being explored, including inhibitors targeting CCL3 or its receptors to mitigate inflammation in autoimmune conditions or block HIV infection. However, its dual role in promoting both tissue repair and pathological inflammation underscores the need for context-specific modulation in clinical interventions.
×
